{"prompt": "['Novartis', 'Confidential', 'Page 59', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', \"investigator's source documents; however, if the AE meets the criteria of an SAE, it must be\", 'reported to Novartis.', '7.2', 'Serious adverse events', '7.2.1', 'Definition of SAE', 'An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)]', 'undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the', 'following criteria:', 'is fatal or life-threatening', 'results in persistent or significant disability/incapacity', 'constitutes a congenital anomaly/birth defect', 'requires inpatient hospitalization or prolongation of existing hospitalization, unless', 'hospitalization is for:', 'routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition (specify what this includes)', 'elective or pre-planned treatment for a pre-existing condition that is unrelated to the', 'indication under study and has not worsened since signing the informed consent', 'treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of a SAE given above and not resulting in hospital admission', \"social reasons and respite care in the absence of any deterioration in the patient's\", 'general condition', 'is medically significant, e.g. defined as an event that jeopardizes the patient or may require', 'medical or surgical intervention.', 'All malignant neoplasms will be assessed as serious under \"medically significant\" if other', 'seriousness criteria are not met.', 'Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of', 'death at the time of the reaction; it does not refer to a reaction that hypothetically might have', 'caused death if it were more severe (please refer to Annex IV, ICH-E2D Guideline).', 'Medical and scientific judgment should be exercised in deciding whether other situations', 'should be considered serious reactions, such as important medical events that might not be', 'immediately life threatening or result in death or hospitalization but might jeopardize the', 'patient or might require intervention to prevent one of the other outcomes listed above.', 'Examples of such events are intensive treatment in an emergency room or at home for allergic', 'bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or', 'development of dependency or abuse (please refer to Annex IV, ICH-E2D Guideline).', 'Any suspected transmission via a medicinal product of an infectious agent is also considered a', 'serious adverse reaction.']['Novartis', 'Confidential', 'Page 60', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '7.2.2', 'SAE reporting', 'To ensure patient safety, every SAE, regardless of causality, occurring after the patient has', 'provided informed consent and until 30 days after the last study visit must be reported to', 'Novartis safety within 24 hours of learning of its occurrence. Any SAEs experienced after the', '30 day period after the last study visit should only be reported to Novartis safety if the', 'investigator suspects a causal relationship to study treatment.', 'All follow-up information for the SAE including information on complications, progression of', 'the initial SAE and recurrent episodes must be reported as follow-up to the original episode', 'within 24 hours of the investigator receiving the follow-up information. An SAE occurring at', 'a', 'different time interval or otherwise considered completely unrelated to a previously reported', 'one must be reported separately as a new event.', 'Information about all SAEs is collected and recorded on the Serious Adverse Event Report', 'Form; all applicable sections of the form must be completed in order to provide a clinically', 'thorough report. The investigator must assess the relationship of each SAE to each specific', 'component of study treatment, (if study treatment consists of several components) complete', 'the SAE Report Form in English, and submit the completed form within 24 hours to Novartis.', 'Detailed instructions regarding the submission process and requirements for signature are to', 'be found in the investigator folder provided to each site.', 'Follow-up information is submitted as instructed in the investigator folder. Each re-', 'occurrence, complication, or progression of the original event must be reported as a follow-up', 'to that event regardless of when it occurs. The follow-up information should describe whether', 'the event has resolved or continues, if and how it was treated, whether the blind was broken or', 'not, and whether the patient continued or withdrew from study participation.', \"If the SAE is not previously documented in the Investigator's Brochure or Package Insert\", '(new occurrence) and is thought to be related to the study treatment a Drug Safety and', 'Epidemiology (DS&E) Department associate may urgently require further information from', 'the investigator for health authority reporting. Novartis may need to issue an Investigator', 'Notification (IN) to inform all investigators involved in any study with the same study', 'treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions', '(SUSARs) will be collected and reported to the competent authorities and relevant ethics', 'committees in accordance with European Union (EU) Guidance 2011/C 172/01 or as per', 'national regulatory requirements in participating countries.', 'Note: SAEs must be reported to Novartis within 24 hours of the investigator learning of its', 'occurrence/receiving follow-up information.', '7.3', 'Liver safety monitoring', 'To ensure patient safety and enhance reliability in determining the hepatotoxic potential of an', 'investigational drug, a standardized process for identification, monitoring and evaluation of', 'liver events has to be followed.', 'The following two categories of abnormalities / adverse events have to be considered during', 'the course of the study (irrespective of whether classified/reported as (S)AE):']\n\n###\n\n", "completion": "END"}